BiotechTube
Home/Inhibikase Therapeutics/Roberto Bellini
RB

Roberto Bellini

Director

Inhibikase Therapeutics

Therapeutic Areas

Cardiopulmonary DiseasePulmonary Arterial Hypertension

Inhibikase Therapeutics Pipeline

DrugIndicationPhase
IkT-001Pulmonary Arterial Hypertension (PAH)Phase 2

Leadership Team at Inhibikase Therapeutics

MI
Mark Iwicki
Chief Executive Officer
DM
David McIntyre
Chief Financial Officer
CC
Chris Cabell
President, Head of Research & Development, Chief Medical Officer
JA
John Adams
Chief Scientific Officer
VA
Vince Aurentz
Director
DB
Dennis Berman
Director
DC
David Canner
Director
View full Inhibikase Therapeutics profile